Why the study?
Multisystem inflammatory syndrome in children is a novel complication of COVID-19, and guidance is needed to help clinicians diagnose and treat this disease.
These recommendations provide a standardized approach for Croatian clinicians to diagnose and treat MIS-C, emphasizing IVIG, glucocorticoids, and long-term cardiac follow-up.
Multisystem inflammatory syndrome in children is a novel entity first described in April 2020. It is a complication of COVID-19 that appears with a latency of 2-6 weeks and is characterized by fever, multiorgan involvement, and elevated inflammatory markers. Diagnosis is based on certain diagnostic criteria, and in these recommendations we chose the World Health Organization case definition. Patients should be treated with intravenous immunoglobulin and glucocorticoids together with other symptomatic and supportive measures. Follow-up should be at least a year-long, and even longer in case of cardiac complications. The aim of these recommendations is to help clinicians in diagnosing and treating this disease.
No takes yet. Share an insight, caveat, or question.
Prtorić et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: